PMID- 37716163 OWN - NLM STAT- MEDLINE DCOM- 20231107 LR - 20231107 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 124 IP - Pt A DP - 2023 Nov TI - PR-957 retards rheumatoid arthritis progression and inflammation by inhibiting LMP7-mediated CD4(+) T cell imbalance. PG - 110860 LID - S1567-5769(23)01185-2 [pii] LID - 10.1016/j.intimp.2023.110860 [doi] AB - OBJECTIVE: Low molecular mass polypeptide 7 (LMP7) is an immunoproteasome subunit that regulates T cell amplification, differentiation, and inflammation and is involved in rheumatoid arthritis (RA) progression. This study intended to apply PR-957 (an anti-LMP7 agent) for RA treatment in vitro and in vivo and evaluate its interaction with LMP7-mediated CD4(+) T cell imbalance. METHODS: Peripheral blood mononuclear cells (PBMCs) were obtained from 30 RA patients and 30 healthy controls. RA fibroblast-like synoviocytes (RA-FLSs) and CD4(+) T cells were isolated from RA patients and then cocultured with PR-957 and/or LMP7 overexpression adenovirus (Ad-LMP7). Collagen-induced arthritis (CIA) mice were constructed and then treated with PR-957 and/or Ad-LMP7. RESULTS: LMP7 was higher in RA patients (versus healthy controls) and positively correlated with T helper (Th)1 cells, the Th1/Th2 ratio, Th17 cells, and the Th17/Treg ratio but not with Th2 or T regulatory (Treg) cells. PR-957 reduced Th1 and Th17 cells but increased Th2 and Treg cells in RA-CD4(+) T cells, and this effect was partially reversed by Ad-LMP7 transfection. Interestingly, when cocultured with RA-CD4(+) T cells, PR-957 increased RA-FLS apoptosis and decreased its invasive ability, viability, and inflammation, as suggested by IL-6, CCL2, MMP1, and MMP3; however, these phenomena were weakened in RA-FLSs without RA-CD4(+) T cell coculture. In addition, Ad-LMP7 transfection attenuated the above effects of PR-957. In CIA mice, PR-957 decreased the arthritis score, synovial hyperproliferation and articular injury, inflammation in the synovium and serum, and the imbalance of Th1/Th2 and Th17/Treg in the spleen, and these effects were attenuated by Ad-LMP7. CONCLUSION: PR-957 ameliorates RA progression and inflammation by repressing LMP7-mediated CD4(+) T cell imbalance. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Liu, Qingyang AU - Liu Q AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Shen, Jin AU - Shen J AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Wang, Jian AU - Wang J AD - Department of Joint Surgery, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Xia, Jinjun AU - Xia J AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Yin, Jian AU - Yin J AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Cheng, Guowei AU - Cheng G AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Qian, Ximing AU - Qian X AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Jiang, Yun AU - Jiang Y AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. FAU - Ge, Xin AU - Ge X AD - Department of Critical Care Medicine, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. Electronic address: gexin2021@suda.edu.cn. FAU - Wang, Qiubo AU - Wang Q AD - Department of Clinical Laboratory, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi 214000, Jiangsu, China. Electronic address: wangqiubo2020@suda.edu.cn. LA - eng PT - Journal Article DEP - 20230914 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Peptides) RN - 0 (PR-957) RN - EC 3.4.25.1 (LMP7 protein) SB - IM MH - Animals MH - Humans MH - Mice MH - *Arthritis, Experimental/drug therapy MH - *Arthritis, Rheumatoid/drug therapy MH - Inflammation MH - Leukocytes, Mononuclear MH - Peptides/pharmacology MH - T-Lymphocytes, Regulatory MH - Th1 Cells MH - Th17 Cells MH - CD4-Positive T-Lymphocytes OTO - NOTNLM OT - CD4(+) T cell imbalance OT - Low molecular mass polypeptide 7 OT - PR-957 OT - Progression and inflammation OT - Rheumatoid arthritis COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/17 00:41 MHDA- 2023/10/23 01:18 CRDT- 2023/09/16 18:05 PHST- 2023/06/27 00:00 [received] PHST- 2023/08/10 00:00 [revised] PHST- 2023/08/23 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/09/17 00:41 [pubmed] PHST- 2023/09/16 18:05 [entrez] AID - S1567-5769(23)01185-2 [pii] AID - 10.1016/j.intimp.2023.110860 [doi] PST - ppublish SO - Int Immunopharmacol. 2023 Nov;124(Pt A):110860. doi: 10.1016/j.intimp.2023.110860. Epub 2023 Sep 14.